SUMMIT THERAPEUTICS ORD 1P overview

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”) will cease to be admitted to trading on AIM at 7.00 am on 24 February 2020. Accordingly, the final day of...

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK, and Cambridge, MA, US, 6 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference on 10 February 2020 at 2:15pm EST in New York City. A live webcast of the presentation will be available in the Investors section of the Company's...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that following the exercise of restricted stock units by former directors, the Company has issued 269,230 new ordinary shares of one penny each (the “New Ordinary Shares”). Application has been made for the admission to trading on AIM...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David Roblin has resigned as Chief Operating Officer, Chief Medical Officer and President of R&D, effective 31 January 2020. “David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our Phase 3 clinical...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA Funding Increased to $62.4 Million Total Award Increased to up to $72.5 Million Oxford, UK, and Cambridge, MA, US, 23 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development...

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate...